Box Office: ‘Michael’ Aims for $70 Million-Plus Debut, Record Start for Music Biopic

"Michael" is tracking to open with $65 million to $70 million in North America, with some exhibitors expecting closer to $80 million, and $75 million to $80 million internationally for a potential $140 million to $150 million global debut by Sunday. The film would mark the biggest opening ever for a musical biopic, though it carries a high $155 million production cost plus tens of millions in reshoots after legal issues forced a major rework. Lionsgate is reportedly hoping for at least $700 million worldwide, which would support sequels if achieved.

Analysis

The setup is less about one film and more about a proof-of-demand event for premium exhibition. If opening-weekend premium mix comes in even modestly above expectations, IMAX and comparable large-format screens should see disproportionate dollar capture because this title is engineered around rewatchable spectacle, not just IP awareness. That matters for the next 4-6 weeks: exhibitors will use the result to justify more premium screens and tighter booking allocations for the next wave of event films, which is a second-order tailwind for the largest-format ecosystem rather than the studio alone.

The bigger market implication is that a strong debut would improve Lionsgate’s negotiating leverage on future music-library-driven projects and reduce perceived financing risk on expensive tentpoles with complicated rights clearances. But the risk/reward is asymmetric: a headline-box-office win can coexist with a weak equity outcome if the film stalls after the first frame, because the cost base and re-cut history imply the studio needs a very long theatrical runway to convert gross into meaningful earnings. The market is likely underestimating how much of the upside is already in pre-sales and premium pricing versus how much downside remains if audience scores soften after opening weekend.

For Disney, the read-through is indirect but useful: a strong adult-skewing theatrical rebound supports the broader thesis that consumers still pay for theatrical ‘event’ content when the brand promise is clear. That helps de-risk its May pipeline and the studio slate more generally, though it does little for the stock unless the momentum translates into multiple title beats rather than a single outlier. Conversely, if this film overperforms while the rest of the box office calendar under-delivers, the market may misread it as a category recovery when it is really a one-off premium-content trade.

The key contrarian point: the consensus is treating this as a clean upside catalyst, but the likely winner is not the studio P&L; it’s the premium exhibition infrastructure and, to a lesser extent, any distributor with strong large-format access. The tradeable signal is the sustainability of the box office rather than the opening number itself. If the movie front-loads and weekday holds are weak, the narrative will reverse quickly over 2-3 weeks.

Key Decisions for Investors

• Long IMAX into opening weekend, then trim into the first print if domestic premium-format share exceeds expectations; upside is strongest if early box office shows >20% mix from premium large formats, with downside capped by event-driven exhibitor demand over the next month.
• Pair trade: long IMAX / short SCOR over 2-6 weeks. The thesis is that premium-content strength is a direct beneficiary for IMAX, while SCOR is a cleaner way to fade any overread that ‘better box office’ translates into broad-based market beta.
• Add DIS on a 1-3 month horizon only on confirmation that this title lifts sentiment around theatrical appetite without cannibalizing May slate attendance; use as a quality-content hedge rather than a standalone catalyst, with ~2:1 upside if the box-office recovery narrative broadens.
• Sell upside in the studio complex if implied valuation starts pricing a franchise outcome from a single release; the risk/reward favors waiting for weekday holds and foreign multiples before extrapolating sequel economics.
• If opening weekend comes in above the high end and IMAX outperforms, consider a short-dated call spread in IMAX to monetize the event-driven re-rating while limiting premium decay after the first earnings-like readout.